Key opportunities in the insulin delivery devices market include advancements in technology leading to user-friendly, ...

Gwyneth Paltrow and neuroscientist Andrew Huberman explore retatrutide, a new triple-agonist GLP-1 therapy said to reduce ...

Hyderabad pharma giant Dr. Reddy’s Laboratories on Wednesday announced the launch of its oral semaglutide biosimilar, marketed under the brand name ‘Obeda®’, for the treatment of Type 2 diabetes ...

As autonomous AI systems make real-time decisions in sensitive domains, runtime governance is emerging as a critical way to ...

We can experience a lot of health changes in midlife, but there are a few simple tests to consider that can bring peace of ...

Researchers evaluated an allogeneic umbilical cord cell therapy in T1DM. A single dose provided durable insulin preservation, ...

Dr Reddy’s Labs launches oral semaglutide biosimilar ‘Obeda’ tablets in India: Our Bureau, Bengaluru Wednesday, May 20, 2026, 17:25 Hrs [IST] Dr Reddy’s Laboratories has l ...

Dr Reddy’s Laboratories launched oral semaglutide biosimilar Obeda in India for type 2 diabetes in 3 mg, 7 mg and 14 mg ...

Detailed price information for Dr. Reddy's Laboratories Ltd ADR (RDY-N) from The Globe and Mail including charting and trades.

The bank holiday weekend is to see temperatures rise across Scotland - but weight loss jag users should be careful ...

The big list of bills in the 2026 Rhode Island legislative session, where they stand and what they do.

Advanced diabetes technology like CGM systems and insulin pumps can help you manage blood sugar fluctuations and make smarter ...